Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis
- 26 November 2001
- Vol. 29 (6) , 553-559
- https://doi.org/10.1016/s8756-3282(01)00615-9
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Protein Geranylgeranylation Is Required for Osteoclast Formation, Function, and Survival: Inhibition by Bisphosphonates and GGTI-298Journal of Bone and Mineral Research, 2000
- Rho-A Is Critical for Osteoclast Podosome Organization, Motility, and Bone ResorptionJournal of Biological Chemistry, 2000
- Compactin Suppresses Bone Resorption by Inhibiting the Fusion of Prefusion Osteoclasts and Disrupting the Actin Ring in OsteoclastsJournal of Bone and Mineral Research, 2000
- Farnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing BisphosphonatesBiochemical and Biophysical Research Communications, 1999
- Rac-GTPase, osteoclast cytoskeleton and bone resorptionEuropean Journal of Cell Biology, 1999
- The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H+-ATPaseJournal of Bone and Mineral Research, 1996
- A possible mechanism of the specific action of bisphosphonates on osteoclasts: Tiludronate preferentially affects polarized osteoclasts having ruffled bordersBone, 1995
- Alendronate increases skeletal mass of growing rats during unloading by inhibiting resorption of calcified cartilageJournal of Bone and Mineral Research, 1994
- The small GTP-binding protein rac regulates growth factor-induced membrane rufflingCell, 1992
- The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factorsCell, 1992